Safety and Tolerability Study of FolateImmune in Combination With Cytokines in Patients With Refractory or Metastatic Cancer

Inclusion Criteria:

* Have a histologically confirmed diagnosis of metastatic or refractory cancer for which there are no effective standard therapeutic options available, (Note: for patients accrued at Southern Illinois University, a diagnosis of renal (i.e., kidney) carcinoma is required.)
* Have signed an Institutional Review Board (IRB) approved informed consent form (ICF) prior to performing any study evaluation/procedures
* Be \> or = 18 years of age and women must either be 1) not of childbearing potential or 2) have a negative serum pregnancy test within 7 days prior to commencing treatment. Patients are considered not of childbearing potential if they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or they are postmenopausal (12 consecutive months of amenorrhea \[lack of menstruation\])
* (If applicable) Have completed prior cytotoxic chemotherapy, radiotherapy or immunotherapy or experimental therapy \> or = 30 days prior to the study enrollment, and recovered form associated toxicities
* Have an Eastern Cooperative Oncology Group (ECOG) score of \< or = 2, and an anticipated life expectancy of at least 6 months
* Have adequate hematologic function, as defined by an absolute or calculated neutrophil count \> or = 1500/microL, platelet count \> or = 100000/microL, lymphocyte count \> or = 500/microL, and hemoglobin level \> or = 10 g/dL. Patients may not receive prophylactic transfusion in order to qualify for trial eligibility
* Have adequate renal function, as defined by a documented serum creatinine of \< or = 2.0mg/dL. Greater than "1+" proteinuria will require microscope evaluation and the results discussed with the medical monitor prior to patient enrollment; or if serum creatine is \>2.0, patient must have an actual or calculated 24-hour creatinine clearance of \>60mL/min and no obvious evidence of concurrent medullary cystic disease or obstructive uropathy
* Have adequate hepatic function, as defined by a total bilirubin level \< or = 1.5 x upper limit of normal (ULN) and alkaline phosphatase, aspartate transaminase (AST), and alanine transaminase (ALT) levels \< or = 2.5 x ULN. If alkaline phosphatase is outside of these parameters and is due to bone metastases (as verified by the assessment of isoenzymes), then the patient is eligible.

Exclusion Criteria:

* Have previously participated in a FolateImmune trial
* Have a history of severe hypersensitivity (grade 3 - 4 allergic reaction) to fluorescein or any drug, radiologic contrast agent, insect bite, food, cytokines, or any other agent; or have received fluorescein within 30 days of the study.
* Have medical conditions that preclude the use of IL-2 or IFN-alpha. These conditions include but are not limited to, diabetes mellitus with a history of progression to diabetic ketoacidosis, history of severe coagulation disorder, psoriasis, sarcoidosis, retinal hemorrhage, symptomatic pulmonary disease, heart failure (\> or = New York Heart Association NYHA class II), or transplant requiring immunosuppressive therapy
* Be pregnant or breast-feeding
* Be currently receiving an experimental drug, or used an experimental device within 30 days of study entry
* Be currently undergoing chemotherapy, anticancer hormonal therapy, and/or therapy with immunosuppressant agents
* Have any concomitant malignancy with the exception of basal cell or squamous cell carcinoma of skin
* Have radiographically documented evidence of current brain metastases, a history of stem cell transplant, immunodeficiency, and/or a medical or psychiatric illness (that in the investigator's opinion, would prevent adequate compliance with study therapy or evaluation of the endpoints)